Inlet Private Wealth’s Charles River Laboratories CRL Stock Holding History

Inlet Private Wealth’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-600	Closed	-$248K	–	135
2021 Q3	$248K	Hold	600	–	–	0.07%	128
2021 Q2	$222K	Buy	+600	New	+$200K	0.06%	126
2020 Q1	–	Sell	-1,500	Closed	-$229K	–	131
2019 Q4	$229K	Buy	+1,500	New	+$208K	0.08%	136
2019 Q3	–	Sell	-1,500	Closed	-$202K	–	145
2019 Q2	$202K	Hold	1,500	–	–	0.07%	144
2019 Q1	$218K	Buy	+1,500	New	+$197K	0.09%	136

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Inlet Private Wealth's CRL Position: Q4 2021 in Review

Inlet Private Wealth sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 600 shares — an estimated $248K sold.

Inlet Private Wealth first reported a position in CRL in Q1 2019 and held it in 5 quarters. The position peaked at $248K in Q3 2021. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

Inlet Private Wealth reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
Inlet Private Wealth sold 600 Charles River Laboratories shares in Q4 2021, an estimated $248K.
Inlet Private Wealth first reported a position in Charles River Laboratories in Q1 2019 and held it in 5 quarters.
Inlet Private Wealth's Charles River Laboratories position peaked at $248K in Q3 2021.
707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on Inlet Private Wealth's 13F filing for Q4 2021, filed 31 Jan 2022.